Aktieanalyser från populära analyshus

24 Mar 09:00

Paxman: From a duopoly to a monopoly - Redeye

Vitrolife: Enters 2025 fighting - Redeye

In the Asian region Vitrolife faces a challenging period.

Momentum Group: Stable niche acquirer with best-in-class management team - Redeye

Scandinavian ChemoTech: Comment on new collaboration - Redeye

Redeye provides a comment on Scandinavian ChemoTech's recently announced collaboration with a global...

ChemoTech

21 Mar 14:20

Analyst Groups kommenterar EMB Mission Bounds Q4-rapport

EMB Mission Bound

21 Mar 12:06

Analyst Group kommenterar på att Cedergrenska erhåller fyra positiva besked från Skolinspektionen

Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 21 mars 2025 att Koncernens nyligen...

Cedergrenska

21 Mar 12:05

Analyst Group kommenterar Obducat - ett bolag inom nanoteknologi som kapitaliserar på starka underliggande marknadstrender

Obducat

21 Mar 12:04

Proact: Deploying capital in the UK - ABG

Acquiring consulting company BlakYaks at 10.7x EV/EBITA Seems to be a good growing and highly profit...

Proact IT

21 Mar 10:13

Rottneros - PW: wood costs, FX, and CTMP - ABG

Paxman: Directed issue - Redeye

Redeye comments on Paxman’s directed issue to institutional investors, raising SEK123.

Paxman

21 Mar 06:53

Pharma Equity Group: Analyst Group Comments on PEG’s Year-End Report for 2024

Xbrane Biopharma: XB003 deal with Alvotech - Redeye

Redeye provides its initial take on Xbrane following the sale of its Cimzia biosimilar (XB003) and p...

Lipigon: Positive Phase I Data from China - Redeye

Lipigon Pharmaceuticals

Analys | Redeye

20 Mar 08:54

Sedana Medical: Confusing clinical data - Redeye

Redeye comments on the clinical data from the SESAR study and the confusion it brought.

Sedana Medical: Confusing clinical data - Redeye

Sedana Medical

19 Mar 14:45

Analyst Group kommenterar Luxbrights ytterligare typgodkännande från Fisica Inc.

Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 19 mars 2025 att Bolaget har erhållit ytter...

Alligator Bioscience: Comment on the reverse split - Redeye

Magle Chemoswed: Initiates post-market study with SmartPAN - Redeye

Redeye leaves a comment following Magle’s announcement of a randomized controlled multicenter trial ...

GomSpace: Directed share Issue of SEK200m to Hargreaves Family - Redeye

Q-linea: Business update and commercial targets for 2025 and 2026 - Redeye

Q-linea’s recent progress in extending the commercial network, establishing a pipeline of ASTar eval...

Ascelia Pharma: FDA feedback confirms that Orviglance is on track for NDA submisison - Redeye

Ascelia Pharma

Analys | Analysguiden

18 Mar 15:44

Redsense Medical: Rekordkvartal och fortsatt tillväxt - Analysguiden

Redsense avslutar 2024 starkt med sitt första helår av vinst.

Redsense Medical

18 Mar 13:35

Infrea: Adopts financial targets - ABG

Infrea

Analys | Analysguiden

18 Mar 13:35

VBG Group: Stabil utveckling trots osäker omvärld - Analysguiden

VBG Group visar fortsatt god lönsamhet trots en utmanande marknad.

Paxman: Takeover offer to Dignitana - Redeye

Dignitana: Takeover offer from Paxman - Redeye

Redeye comments on Dignitana’s takeover offer from Paxman, valued at SEK153m (SEK1.

Dignitana

18 Mar 09:42

Petrolia Noco: Brage reserve uplift boosts production outlook - ABG

Petrolia

Analys | Analysguiden